Skip to main content
EJNMMI Research

Table 1 Ex vivo biodistribution of 99m Tc-J591Cdia at 8 h post injection

From: Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)

Organ

DU145-PSMA

DU145

Tumour

12.1 ± 1.7

6.3 ± 0.5

Blood

1.5 ± 0.2

1.9 ± 0.4

Stomach

1.4 ± 0.3

2.2 ± 0.1

Small intestine

1.4 ± 0.2

2.4 ± 0.2

Large intestine

1.7 ± 0.3

2.7 ± 0.3

Spleen

10.1 ± 2.8

18.0 ± 1.2

Liver

13.0 ± 1.8

20.5 ± 2.5

Kidneys

29.2 ± 3.5

51.4 ± 3.2

Heart

2.7 ± 0.3

5.8 ± 0.5

Lungs

5.5 ± 1.2

6.0 ± 0.6

Muscle

0.7 ± 0.2

1.3 ± 0.3

Bone

2.0 ± 0.4

4.0 ± 0.4

Reproductive organs

1.8 ± 0.7

3.2 ± 0.4

Salivary glands

2.4 ± 0.7

4.5 ± 0.4

Skin

1.4 ± 0.4

3.1 ± 0.5

Tumour to blood ratio

8

3.3

Tumour to muscle ratio

16.8

4.8

Ratio of DU145-PSMA to DU145 tumour uptake

1.9

-

  1. Ex vivo biodistribution of 99mTc-J591Cdia in mice with subcutaneous DU145 or DU145-PSMA tumours at 8 h post injection (n = 4). Values are expressed as mean percent injected dose per gram of tissue (% ID/g) ± SD.
Back to article page